Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) is a radioembolization drug designed to treat a variety of solid organ tumors, such as primary liver cancer, hepatocellular carcinoma (HCC), and secondary liver cancer, metastatic colorectal cancer (mCRC).
We are currently evaluating the safety and efficacy of 188RNL-BAM in preclinical trials. We have received licensed patents and technologies for the development of 188RNL-BAM from The University of Texas Health Science Center at San Antonio.
188RNL-BAM consists of alginate microscale particles, tailored for vascular radioembolization and containing thousands of nanoliposomes with the radioisotope, Rhenium-188. As opposed to non-biodegradable implants (like glass or resin) that do not break down easily and are essentially permanent, alginate is a nontoxic, biocompatible and biodegradable material that is widely recognized as safe.
Alginate microspheres are designed to not only to block blood flow to the tumor, which in itself helps kill the tumor, but also carry the radioisotope to the tumor area where the radiation will eventually decay, becoming harmlessly absorbed and cleared by the body.
188RNL-BAM is administered through a 2-step, minimally invasive procedure called trans-arterial radioembolization (TARE). It is performed on an outpatient basis on two separate days, where the drug is infused through a microcatheter into the hepatic artery, inducing selective tumor necrosis.
HCC is the most common type of primary liver cancer and has few effective treatment options at an advanced stage. mCRC is an advanced secondary liver cancer that has spread to the liver from the breast, lung, colon or rectum and is difficult to treat when unresectable.